Relay Therapeutics (RLAY) FY Conference June 11, 2025 02:40 PM ET Speaker0 Good afternoon, everyone. Thank you so much for joining us. I'm Salveen Richter, biotechnology analyst at Goldman Sachs. Really pleased to have with me Sanjeev Patel, President and CEO of Relay. Sanjeev, to start here, could we just level set here with an overview of the Dynamo platform and where you stand today with the optimization efforts that have played out and the acquisitions of technologies, as well as pipeline strategy and u ...

Olema Pharmaceuticals (OLMA) 2025 Conference June 04, 2025 11:40 AM ET Speaker0 Good afternoon. How are you? Thank you for joining us on the next panel discussion here. I am very fortunate to have the CEO of Olima Pharmaceuticals here, Sean Bowen. Sean is continuing to work on developing and executing on his breast cancer drug, palazestrin. Obviously we just came away from ASCO and continue to learn more about the developments in breast cancer. And so I would love, Sean, maybe just to give a snapshot view. ...

Updated interim data remain consistent, showing 10.3-month median PFS overall and 11.0-month median PFS in 2L patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer Data continue to support planned initiation of pivotal study in mid-2025 Next-generation triplet combinations with atirmociclib (CDK4-selective) & ribociclib ongoing CAMBRIDGE, Mass., June 02, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery pro ...

Cash runway extended into 2029 Initiation of Phase 3 ReDiscover-2 trial on track for mid-2025 Initiated Phase 1 RLY-2608 vascular malformations clinical trial in Q1 Extended cash runway expected to fully fund the Company meaningfully past topline data for ReDiscover-2 trial and through clinical proof-of-concept data in Vascular Malformations Approximately $710 million in cash, cash equivalents and investments at end of Q1 2025 CAMBRIDGE, Mass., May 05, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nas ...